|
|
4. Achieving treatment
goals in the management of diabetes Sunday,
September 17, 2000
09:00 - 11:30
| 09:00-09:10
|
Chairperson's introduction |
| 09:10-09:30
|
The framework of diabetes care:
allowing patients to have a normal fulfilled life |
| 09:30-09:55
|
Studies on the prevention of type
1diabetes |
| 09:55-10:20 |
Use of Insulin: A means to
delay type 2 diabetes progression |
| 10:20-10:45
|
Novel routes of insulin delivery
for patients with type 1 and type 2 diabetes |
| 10:45-11:10
|
Treatment evolution: redefining
treatment paradigms for type 2 diabetes |
| 11:10-11:25
|
Questions/panel discussion |
| 11:25
|
Chairperson's summary |
ICC - Jerusalem International Convention Center - Hall G
Werner Scherbaum, German Diabetes Research Institute, Duesseldorf, Germany
Pfizer
Aventis Pharma
 FOR
GENERAL ENQUIRIES
Jennifer Zar, Professional Relations Associate
Pfizer Inc., 235 East 42nd Street
New York, NY 10017-5755, USA
Tel: +1 212 733 4896
Fax: +1 212 716 5510
E-mail: zarj@pfizer.com
OR
Siobhan Southam, Client Business Manager
Adelphi Communications Ltd
Adelphi Mill, Grimshaw Lane, Bollington
Macclesfield, Cheshire, SK10 5JB, UK
Tel: +44 1625 577247
Fax: +44 1625 575853
E-mail: siobhan.southam@adelphi.co.uk
FOR
REGISTRATION ENQUIRIES
Helen Capelin
PPSI, 3 Liverpool Gardens
Worthing, West Sussex BN11 1TF, UK
Tel: +44 1903 703044
Fax: +44 1903 703001
E-mail: hcapelin@hbase.com
|
